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Background: Although the prevalence of anaphylaxis is increasing worldwide, the large-scale
studies in Asia evaluating anaphylaxis in all age groups are limited. We aimed to collect more pre-
cise and standardized data on anaphylaxis in Korea using the first multicenter web-based registry.
Methods: Twenty-two departments from 16 hospitals participated from November 2016 to
December 2018. A web-based case report form, designed by allergy specialists, was used to
collect anaphylaxis data.
Results: Within the 2-year period, 558 anaphylaxis cases were registered. The age of registered
patients ranged from 2 months to 84 years, and 60% were aged <18 years. In children and ado-
lescents, foods (84.8%) were the most common cause of anaphylaxis, followed by drugs (7.2%); in
adults, drugs (58.3%) were the most common cause, followed by foods (28.3%) and insect venom
(8.1%). The onset time was 10 min in 37.6% of patients. Among the 351 cases registered via the
emergency department (ED) of participating hospitals, epinephrine was administered to 63.8% of
patients. Among those receivingepinephrine in theED,13.8% required2ormoreepinephrine shots.
Severe anaphylaxis accounted for 23.5% cases (38.1% in adults; 13.7% in children); patients with
drug and insect venom-induced anaphylaxis had higher rates of severe anaphylaxis.
Conclusion: This multicenter registry provides data on anaphylaxis for all age groups for the first
time in Asia. The major causes and severity of anaphylaxis were remarkably different according to
age group, and the acute treatment features of anaphylaxis in the EDs were examined in detail.
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Anaphylaxis, a severe and life-threatening sys-
temichypersensitivityreaction,ismostlytriggeredby
food, drugs, or insect venom.1,2 The expected
lifetime prevalence of anaphylaxis is 0.05%–2%;3,4
recent studies show a profoundly rising trend.5–8
Food is the most common trigger of anaphylaxis in
children, whereas drugs and insect venomaremore
common causes in adults.9 However, anaphylaxis
patterns according to different age groups have not
been adequately studied in a large population.
Through the European Anaphylaxis Registry,
established in2007, valuable information regarding
the clinical features of anaphylaxis have been
collected and published.9–11 The use of
intramuscular epinephrine to treat anaphylaxis is
still suboptimal,9 despite being the first-line treat-
ment recommended by international guidelines. In
Korea, previous anaphylaxis studies were mostly
retrospective medical chart reviews focusing on
specific age groups, either children or adults.12,13
Recent big data analyses on anaphylaxis are useful
in investigating the epidemiology or trends over a
period of time;14,15 however, limitations exist as
some factors such as eliciting triggers, severity, or
treatment cannot be identified through the national
big data. Hence, we developed a multicenter web-
based registry to investigate the triggers, clinical
features, and treatment details of anaphylaxis in
Koreanpatients, includingall agegroups.METHODS
Study design and participants
Allergy specialists from 22 departments in 16
tertiary or secondary hospitals in Korea took part in
this registry from November 2016 to December
2018. Participation of allergy centers was volun-
tary; this study was approved by the institutional
review board of each hospital. Patient recruitment
involved identification of anaphylaxis cases by
participating allergists at the time of admission
from the emergency department (ED) or at the
follow-up outpatient department (OPD) visit. In the
case of anaphylaxis patients who had been treated
at another hospital for acute anaphylactic symp-
toms and visited the OPD of a participating hos-
pital for further workup or long-term management,
cases managed within the last 3 months from the
visit day with an identifiable date of anaphylaxiswere included. After obtaining written consent, the
allergist completed a standardized case report
form (CRF). The diagnosis of anaphylaxis was
based on the criteria published in 2006 by the
National Institute of Allergy and Infectious Disease
and the Food Allergy and Anaphylaxis Network.2
Web-based registry and variables
The data assessed by the web-based systematic
CRF developed by allergy specialists in this registry
were date of anaphylactic reaction, date of hospital
visit, routeofvisit toparticipatinghospitals (ED,OPD,
or ward), demographic profiles, medical history,
family history of allergic diseases, triggers of current
anaphylactic reaction, time of symptom onset after
exposure to the trigger, place of occurrence, symp-
tom profile, presence of cofactors, acute treatment
details, and laboratory tests performed. In the anal-
ysis, adult participantsweredivided intoagegroups
with 10-year intervals; pediatric and adolescent par-
ticipants were categorized as infants (<24 months),
preschool children (2–6 years), schoolchildren (7–12
years), andadolescents (13–17years) to illustrate the





All analyses were conducted using SPSS 20.0 for
Windows (SPSS, Inc., Chicago, IL, USA). This study
mainly contains raw, stratified description of vari-
ables. Categorical variables were expressed as a
percentage or ratio. Comparison between groups
was performed using Fisher's exact test. P
values < 0.05 were considered significant. Missing
data were minimized by configuring the final save
of the web-based CRF only when essential vari-
ables were completed.
RESULTS
Participating centers and participants’
demographic data
The data of 558 participants from 16 centers in
Korea were obtained. Of these, 351 (62.9%) pa-
tients visited the EDs of participating hospitals
during acute anaphylaxis episodes; 35.1% visited
the OPDs of participating centers after acute
anaphylaxis episodes; and 2.0% experienced
Volume 13, No. 8, Month 2020 3anaphylaxis in the wards. Women accounted for
45.2%; female sex was predominant in adults
(56.5%) compared to in children (37.6%). Children
aged <18 years accounted for 60% of the regis-
tered patients. Among children and adolescents,
the proportion of preschool children (2–6 years)
was the highest, followed by infants (<24 months)
and schoolchildren (7–12 years). Among adults,
the proportion of middle-aged patients aged 40–




























Family history of allergic diseases
Table 1. Participants’ demographic profile. a. Most of the participants hadallergy was the most common comorbidity in
children, followed by atopic dermatitis, allergic
rhinitis, previous anaphylaxis, and asthma. The
percentages of food allergy and atopic dermatitis
were remarkably lower in adults than in children,
while the percentage of drug allergy was higher
in adults than in children. Family history of
allergic diseases was present in 76.1% of children

















<18 years 18 years
36 (10.7) 11 (4.9)
98 (29.3) 62 (27.8)
159 (47.5) 9 (4.0)
12 (3.6) 5 (2.2)
72 (21.5) 37 (16.6)
203 (60.6) 41 (18.4)
16 (4.8) 24 (10.8)
0 (0.0) 14 (6.3)
0 (0.0) 33 (14.8)
0 (0.0) 6 (2.7)
n (%)
<18 years 18 years
255 (76.1) 71 (31.8)
more than one comorbidity
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Of the 558 cases, food (62.2%) was the most
common cause of anaphylaxis, followed by drugs
(27.6%), insect venom (3.4%), food-dependent
exercise-induced anaphylaxis (FDEIA, 2.0%), and
exercise (0.4%). Other triggers such as cat fur,
feather of unknown bird, hair dye, and bee pollen
accounted for 1.1%. Specific anaphylaxis triggers
were not identified in 3.4% of patients. Patterns of
anaphylaxis triggers were remarkably different in
children and adults (Fig. 1 A). In children (age <18
years, n ¼ 335), food accounted for 84.8%,
followed by drugs (7.2%); in adults (n ¼ 223),
drugs (58.3%) were a more common trigger than
food (28.3). Insect venom-induced anaphylaxis
was observed only in 0.3% of children, but the
percentage was relatively high (8.1%) in adults.
Exercised-induced anaphylaxis was observed in
0.3% of children and 0.4% of adults. On sub-
analysis, the pattern of anaphylaxis trigger was
distinct in every age group (Fig. 1 B and C). Food
was the most common cause of anaphylaxis in
infants (98.9%), and the proportion of food-
induced anaphylaxis decreased as age increased.
The proportion of drug-induced anaphylaxis
increased as age increased (Fig. 1 C). The
percentage of idiopathic anaphylaxis was higherFig. 1 Triggers of anaphylaxis. (a) In overall. (b) By age groups. (c) In chi
exercise-induced anaphylaxisin older children than in younger children. In
adults, the proportion of food-induced anaphy-
laxis was higher in young adults, and the per-
centage of drug-induced anaphylaxis was higher
in patients in their 40s (68.5%) and 60s (70%). The
percentage of insect venom-induced anaphylaxis
was higher in older patients than in young adults.
Of the 284 cases of food-induced anaphylaxis in
children, hen's egg was the most common cause,
followed by cow's milk, walnuts, wheat, and peanut
(Table 2). Other food triggers, which accounted for
more than 5 cases each, in children were kiwi
(n ¼ 12), pine nuts (n ¼ 11), buckwheat (n ¼ 9),
and soybean (n ¼ 5). Minor food triggers
included cashew nuts (n ¼ 4), shrimp (n ¼ 4),
unspecified tree nuts (n ¼ 3), fish (n ¼ 3),
vegetables (n ¼ 3), pistachio, hazelnuts, mango,
almonds, peach, apple (2 cases each),
macadamia nuts, mulberry, banana, strawberry,
grape, melon, crab, unspecified crustaceans, and
shellfish (1 case each). Other uncategorized food
triggers included multiple foods taken at the
same time or consumption of processed food
products. Of the 24 cases of drug-induced
anaphylaxis in children, analgesics accounted for
54.2%, followed by antibiotics (16.7%). The
detailed individual drug list of causative analgesicsldren and adolescents by age sub-groups. FDEIA: food-dependent
Triggers n (%b)
Children and adolescents (<18 years) Food Hen's egg 72 (25.4)





Pine nut 11 (3.9)
Buckwheat 9 (3.2)
Soybean 5 (1.8)
Other foods 60 (21.1)
Drugs Analgesics 13 (54.2)
Antibiotics 4 (16.7)
Other drugs 7 (29.1)







Other foods 25 (39.7)
Drugs Antibiotics 65 (50.0)
Analgesics 24 (18.5)
H2 blockers 23 (17.7)
Radiocontrast media 2 (1.5)
Other drugs 16 (12.3)
Table 2. Specific food triggers and drug triggers of anaphylaxis. b. Refers to the percentage within the same category
Volume 13, No. 8, Month 2020 5and antibiotics in children is described in the
Supplemental Table 1. Other drug triggers
included H2 histamine receptor antagonist,
vaccines, and traditional medicine.The patterns of food- and drug-induced
anaphylaxis differed between children and adults.
In 63 adult cases of food-induced anaphylaxis,
shrimp was the most common cause, followed by
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by soybean, peanuts, beef, and pork, respectively,
were reported. The food triggers in adults were
mango, melon, plum, cow's milk, almonds, mac-
adamia nuts, unspecified vegetable, buckwheat,
unspecified crustaceans, cuttlefish, and pupa, with
1 case for each trigger. Among the 130 cases of
drug-induced anaphylaxis in adults, antibiotics
accounted for 50%, among which cefaclor was the
most common culprit. Analgesics, H2 histamine
receptor antagonist, and radiocontrast media were
among the drugs that trigger anaphylaxis in adults,
while minor drug triggers in adults included an-
esthetics and chemotherapeutic agents. The
detailed individual drug list of causative antibi-
otics, analgesics, and H2 histamine receptor an-
tagonists in adults is described in the
Supplemental Table 1.
The percentages of patients in whom serum
tryptase levels, total immunoglobulin E, and tests
for anaphylaxis cause were performed were
23.8%, 81.4%, and 81.4%, respectively. The pro-
portion of patients who were tested to determine
the cause of anaphylaxis was 84.2% in children
and 77.1% in adults (results not described in this
paper).
Symptom profile, onset time, places of
occurrence, and cofactors
Cutaneous symptom was observed in >90% of
patients in both children and adults (Table 3),
followed by respiratory (83.2%), gastrointestinal
(48.9%), neurologic (30.3%), and cardiovascular
(28.1%) symptoms. Compared with children,
cardiovascular and neurologic symptoms were
significantly higher in adults. Among detailed
symptom profiles, there was a higher percentage
of itching symptom in adults, whereas oral
mucosal symptoms were more common in
children. The percentage of respiratory symptoms
was similar in children and adults; the proportion
of rhinorrhea, stridor, cough, wheezing, and
cyanosis was significantly higher in children,
while that of dyspnea was higher in adults.
Among gastrointestinal symptoms, the proportion
of nausea, diarrhea, and abdominal pain was
significantly higher in adults. Most of the
cardiovascular symptoms were more commonly
observed in adults, except pallor. Among
neurologic symptoms, the proportion of dizzinessand loss of consciousness was significantly higher
in adults.
Information on symptom onset time was avail-
able for 507 of 558 cases (311 children and 196
adults). Among these, symptom onset time was
10 minutes in 41.4%, 10–30 minutes in 30.6%,
between 30 minutes and 2 hours in 21.3%, and
>2 hours in 6.7%. In both children and adults, the
most common place of anaphylaxis occurrence
was the patient's own home (Table 4). Other major
places of occurrence included restaurants,
childcare centers, schools, workplaces, outdoors,
and other people's homes. The anaphylaxis cases
reported in hospitals occurred during oral food
challenge tests.
Cofactors were present in 16.8% of the partici-
pants, absent in 64.8%, and the presence of co-
factors was not definite in 18.5%. In children,
cofactors were present in 18.8%, with acute infec-
tious illness (n ¼ 26) as the most common cofactor.
The other cofactors in children included exercise
(n ¼ 17), major change in lifecycle such as travel
(n ¼ 5), and menstruation (n ¼ 2). In adults, co-
factors were present in 13.9%, with exercise (n ¼ 9)
being the most common cofactor. The other co-
factors in adults included alcohol intake (n ¼ 5),
sleep deprivation (n ¼ 4), acute infectious illness
(n ¼ 2), and mental stress (n ¼ 2). Other minor
cofactors both in adults and children included
extreme temperatures, vaccination, and excessive
physical activities.Emergency treatment of anaphylaxis and
progress
We analyzed the treatment details of the 351
patients (190 children and 161 adults) who visited
the ED of participating hospitals at the time of
acute anaphylaxis event. The epinephrine admin-
istration rates were 66.7% and 61.3% in children
and adults, respectively; the administration rates of
intravenous fluids, systemic steroids, or H1 anti-
histamine were higher than that of epinephrine
(Fig. 2). Among the 224 patients (124 children and
98 adults) receiving epinephrine in the ED,
epinephrine was administered within 1 hour of
ED arrival in 91.2% of children and 81.6% of
adults (Table 5). The route of epinephrine
administration was intramuscular in 90.5% of




<18 years 18 years
Cutaneous 317 (94.6) 207 (92.8) 0.636
Itching 135 (40.3) 133 (59.6) <0.001
Urticaria 235 (70.1) 148 (66.4) 0.353
Erythema 112 (33.4) 63 (28.3) 0.226
Angioedema 168 (50.1) 116 (52.0) 0.667
Pruritus and swelling of lips-tongue-uvula 66 (19.7) 23 (10.3) 0.003
Respiratory 279 (83.3) 185 (83.0) 0.294
Rhinorrhea 30 (9.0) 7 (3.1) 0.008
Stridor 15 (4.5) 0 (0.0) 0.001
Dyspnea 168 (50.1) 182 (81.6) <0.001
Cough 141 (42.1) 10 (4.5) <0.001
Wheezing 95 (28.4) 8 (3.6) <0.001
Cyanosis 24 (7.2) 4 (1.8) 0.005
Gastrointestinal 163 (48.7) 110 (49.3) 0.410
Nausea 36 (10.7) 67 (30.0) <0.001
Vomiting 108 (32.2) 66 (29.6) 0.516
Diarrhea 9 (2.7) 31 (13.9) <0.001
Abdominal pain 57 (17.0) 72 (32.3) <0.001
Cardiovascular 61 (18.2) 96 (43.0) <0.001
Chest pain 16 (4.8) 22 (9.9) 0.025
Pallor 26 (7.8) 4 (1.8) 0.002
Collapse 4 (1.2) 12 (5.4) 0.007
Diaphoresis 4 (1.2) 12 (5.4) 0.007
Hypotension 22 (6.6) 64 (28.7) <0.001
Arrest 0 (0.0) 0 (0.0) N/A
Neurologic 60 (17.9) 109 (48.9) <0.001
Dizziness 23 (6.9) 75 (33.6) <0.001
Anxiety 12 (3.6) 12 (5.4) 0.394
Paresthesia 1 (0.3) 1 (0.4) 1.000
Weakness 30 (9.0) 17 (7.6) 0.642
Confusion 0 (0.0) 2 (0.9) 0.159
Loss of consciousness 1 (0.3) 38 (17.0) <0.001
Death 0 (0.0) 0 (0.0) N/A
Table 3. Clinical manifestations of anaphylaxis. c. More than one symptom was recorded in each case. d. Fisher's exact test
Volume 13, No. 8, Month 2020 7epinephrine shots administered in the ED were as
follows: 1, 84.9% children and 63.3% adults; 2,
10.3% children and 18.4% adults; and 3, 3.2%
children and 7.1% adults.
After acute anaphylaxis treatment in the ED,
43% patients were hospitalized (41%, general
wards; 2%, intensive care unit) for further treatmentor close observation. A biphasic reaction was
observed in 4.3% of patients, while a sustained
reaction was observed in 2.3%. After acute
anaphylaxis treatment in the ED, epinephrine
autoinjector was prescribed to 59% of patients,















Fig. 2 Treatment details of anaphylaxis patients in the emergency departments of participating hospitals. IV: intravenous, H1-AH: H1
antihistamine, H2-AH: H2 antihistamine, BD: bronchodilator
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Severe anaphylaxis combined with hypoxia, hy-
















Table 4. Symptom onset time and places of occurrence of anaphylaxis
f. Cases that were reported in hospitals occurred during oral food challenge testo Brown's classification16 was observed in 23.5%
of patients; the percentage of severe anaphylaxis
increased with age (Fig. 3 A). The percentage of






<18 years 18 years
193 (57.6) 94 (42.2)
11 (3.3) 5 (2.2)
30 (9.0) 11 (4.9)
30 (9.0) 0 (0.0)
26 (7.8) 3 (1.3)
0 (0.0) 7 (3.1)
16 (4.8) 20 (9.0)
17 (5.1) 20 (9.0)
11 (3.3) 6 (2.7)
1 (0.3) 57 (25.6)
. e. Refers to the percentage of cases with records of symptom onset time.
ts
Details of epinephrine administration in ED
n (%g)
<18 years 18 years
Epinephrine administration time after arrival to ED
1 hour 115 (91.2) 80 (81.6)
>1 hour 7 (5.6) 8 (8.2)
Uncertain 4 (3.1) 10 (10.2)
Route of epinephrine administration
Intramuscular 114 (90.5) 78 (79.6)
Intravenous 8 (6.3) 7 (7.1)
Subcutaneous 0 (0.0) 1 (1.0)
Others 2 (1.6) 2 (2.0)
Uncertain 2 (1.6) 10 (10.2)
Number of epinephrine shots administered
1 107 (84.9) 62 (63.3)
2 13 (10.3) 18 (18.4)
3 4 (3.2) 7 (7.1)
Uncertain 2 (1.6) 11 (11.2)
Table 5. Details of epinephrine administration in the emergency department g. Refers to the percentage among cases in which epinephrine was















































Fig. 3 Severity of anaphylaxis. (a) By age group. (b) By triggers. FDEIA: food-dependent exercise-induced anaphylaxis
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http://doi.org/10.1016/j.waojou.2020.100449infants aged <24 months; 13.3%, preschool
children (2–6 years); 11.9%, schoolchildren (7–12
years); and 31.3%, adolescents (13–17 years). The
percentage of severe anaphylaxis in adults was
38.1%: 24.4%, patients aged 18–29 years; 29.4%,
patients in their 30s; 37%, patients in their 40s;
47.9%, patients in their 50s; 46.7%, patients in
their 60s; and 58.3%, patients aged 70 years.
The proportion of severe anaphylaxis according
to the triggers is presented in Fig. 3 B. The
percentage of severe anaphylaxis was the highest
in insect venom-induced anaphylaxis (57.9%), fol-
lowed by exercise-induced anaphylaxis (50%),
drug-induced anaphylaxis (36.4%), FDEIA (36.4%),
idiopathic anaphylaxis (31.6%), and food-induced
anaphylaxis (15%).DISCUSSION
Through this first web-based multicenter regis-
try in Asia, we were able to collect and present a
broad and detailed understanding of the clinical
features of anaphylaxis. Due to the large number
of anaphylaxis cases at all ages, we could track the
differences in clinical profiles according to age,
especially the profoundly different triggers be-
tween infants and older patients. Additionally,
assessing the concomitant comorbidities may
allow future identification of severe allergic
reactions.
The concomitant allergic history of patients in
this study was similar to that reported in previous
studies, with atopic dermatitis being the most
common in children, and allergic rhinitis being the
most common in adults.10,17 The proportion of
children with asthma was relatively higher in the
European registry than that in our region,
possibly due to the variance in the age
distribution of patients registered in each study
and the difference in the prevalence of asthma.18
Unlike other studies, we classified that a
previously known food allergy is a separate
medical history and identified that >50% of
children in this registry had a previously known
food allergy.
Due to the relatively large data used, we were
able to present the continuous shift from food-
induced anaphylaxis toward drug-induced and
insect venom-induced anaphylaxis with increasing
age, consistent with previous studies.6,10,19,20 Theinsect venom-induced anaphylaxis was remarkably
more common in older patients, as reported pre-
viously.11,20–22 The percentage of insect venom-
induced anaphylaxis was remarkably higher in
Europe than in our region both in adults and
children, although the reasons for the difference
are not clear. The proportion of insect venom-
induced anaphylaxis from a multicenter study in
Singapore was quite compatible with that reported
in our study both in adults and children.23 Hen's
egg and cow's milk were the top 2 food triggers
in children, as reported previously studies;
walnuts were identified as an unusually common
food trigger in our region, while peanuts were a
more common trigger in most Western
studies.10,24 Walnuts are consistently identified
as a common food allergen in children in our
region and ranked third or fourth in previous
Korean studies.12,25,26 As the distribution of food
allergens reflects the distinctive eating habits in
different regions, the relatively lower intake of
peanuts and progressively increasing
consumption of walnuts as an ingredient of
various Korean cuisines may explain this result.
By dividing children and adolescents into
subgroups according to age, a progressive
decrease in the proportion of patients reporting
food as the trigger and a constant increase in the
proportion of patients reporting drugs as the
trigger was observed from infants to adolescents.
This finding is consistent with those of previous
studies,10,20 but the differences in triggers
among infants, preschoolers, schoolchildren, and
adolescents are a fairly unique and significant
finding. Hence, our results indicate that detailed
distribution of triggers by age would be useful
for age-specific management and anaphylaxis
prevention along with patient education.
Cutaneous symptoms as the most common
manifestation have been reported; the prevalence
of respiratory and gastrointestinal symptoms was
relatively higher in this study, while that of cardio-
vascular symptomswas low;6,9 this may be because
60%of the registeredpatientswereaged<18years.
The prevalence of cardiovascular and neurologic
symptoms was higher in older patients, consistent
with previous reports,11 due to the higher
proportion of preexisting cardiovascular
comorbidities and more frequent use of
cardiovascular drugs in older patients or the
Volume 13, No. 8, Month 2020 11differences in the prevalence of triggers between
adults and children or in both age groups. In
addition to the symptom outline according to
organ system, the detailed symptom profiles
within each system were compared between
adults and children. Although the percentages of
cutaneous, respiratory, and gastrointestinal
symptoms were similar in children and adults, the
symptom details were noticeably different.
Significantly higher proportions of children had
wheezing, consistent with previous reports, while
remarkably higher proportions of adults had
abdominal pain and diarrhea, inconsistent with
previous reports.27 The most common place of
anaphylactic reaction occurrence was the patient's
own home, consistent with previous reports.24 The
distribution of places of occurrence in children
was comparable with those of previous studies,
except that the rates of occurrence in schools,
childcare centers, or restaurants were relatively
higher in our study.10,24 This is due to the fact that
children in Korea eat school meals instead of
bringing homemade food, and are spending more
time outside their homes and consuming food
prepared outside their homes.
The higher rates of severe anaphylaxis with
increasing age were consistent with previous re-
sults.11,13 In the analysis of the severity of
anaphylaxis according to the trigger, the risk of
severe anaphylaxis was particularly higher in
patients with drug- or insect venom-induced
anaphylaxis than in those with food-induced
anaphylaxis. Moreover, the severity of anaphylaxis
was higher in patients with drug-induced anaphy-
laxis than in those with food-induced anaphylaxis,
which was also reported in other studies;13,28
however, the number of studies evaluating the
potential risk factors for severe anaphylaxis are
limited. We identified increasing age, anaphylaxis
history, and presence of cofactors (specific data
not shown) as significant risk factors for severe
anaphylaxis; further analysis will be conducted as
more data are collected in this registry.
Acute infectious illness and physical exercise are
the most frequently reported cofactors in children,
which was compatible with those in the European
registry, whereas the distribution of major co-
factors in adults was rather diverse between
studies. Physical exercise was the most common
cofactor of anaphylaxis in adults in this study,whereas drug intake or tiredness was a more
common cofactor among adults in other
studies.29,30 To date, little is known about the
cofactors affecting the induction and
augmentation of severe allergic reactions. In
future studies, cofactors related with anaphylaxis
should be more thoroughly evaluated so that
patients can be better informed about the risk
factors amplifying severe allergic reactions.
Although the international guidelines for the
acute management of anaphylaxis recommend the
intramuscular administration of epinephrine as
first-line treatment,31,32 the proportion of acute
anaphylactic patients receiving epinephrine is not
high enough, with contrasting rates varying from
study to study.9,33,34 The proportion of patients
who received epinephrine in the EDs of
participating hospitals (66.7% in children and
61.3% in adults) was similar or slightly higher
than those reported in previous studies, partly
because the data were obtained from secondary
or tertiary hospitals and due to the growing
awareness of medical personnel on the acute
management of anaphylaxis. A recent study has
reported clinically and statistically significant
increases in epinephrine administration, in
concordance with epinephrine-related guidelines
for food-induced anaphylaxis, in the past 15 years
in the EDs in the United States and Canada.35 One
of our study strengths related to acute treatment
was that the epinephrine administration time,
route of administration, and number of
epinephrine shots required were investigated
and analyzed in detail. In a recent report from
the European registry, 3.3% of anaphylaxis
patients who did not receive epinephrine before
the start of professional emergency management
received more than 1 epinephrine dose.36 The
higher rates of adults requiring 2 or more shots
of epinephrine are most probably related to the
greater proportion of severe anaphylaxis in
adults. This is an important data, which suggests
that there may be a considerable proportion of
patients with anaphylactic reactions who do not
show improvements in symptoms after receiving
a single shot of epinephrine. The proportion of
epinephrine administered intramuscularly was
higher in our study than that in the European
registry, in which 36.3% patients received
epinephrine intravenously.36
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the participating hospitals were mostly tertiary
hospitals andwere selected based on the clinicians’
interest in establishing this registry. Only patients
who provided written consent were included, and
the reporting was voluntarily conducted by the
participating clinicians. However, given that all
registries of allergic diseases, including the largest
existing anaphylaxis registry in Europe, are collect-
ing informationby voluntary reportingof healthcare
professionals, the results of this study are mean-
ingful as yielding an extensive and heterogeneous
data covering all age groups. The ongoing opera-
tion of this registry will enable the collection of
larger-scale data on anaphylaxis and thus will reveal
more about the rare causes of anaphylaxis.
CONCLUSION
This multicenter web-based anaphylaxis regis-
try, the first registry established in Asia, has pro-
duced in-depth reporting on 558 anaphylaxis
cases in the first 2 years and will be valuable for
collection of systematic and standardized data on
anaphylaxis in the future. Furthermore, noting
trends over time will provide changes in the trig-
gers, clinical manifestations, and treatment of
anaphylaxis and therefore improve the overall
management of the disease.
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